Navigation Links
Sangamo BioSciences Announces Presentation At Regen Med Investor Day
Date:4/11/2013

RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray , this flagship event features 16 of the regenerative medicine field's leading small- and mid-cap companies.

The following are specific details regarding Sangamo BioSciences' presentation at the conference:Event:

ARM's Regen Med Investor DayDate:

April 17, 2013Time:

2:45pm ESTLocation:

Harmonie Club, 4 East 60th Street, New York, NY 10022The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on both the Sangamo and ARM websites after the event.

The event also includes disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas , President of Shire Regenerative Medicine and Kieran Murphy , President and CEO, GE Healthcare Life Sciences.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.

About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
2. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Reports First Quarter 2012 Financial Results
8. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2020)... , ... May 04, 2020 , ... ... solutions for the life sciences industry, today announced that Informa Training Partners, a ... changing its name to Red Nucleus Boston, effective immediately. , “The name change ...
(Date:5/1/2020)... YORK (PRWEB) , ... April 30, 2020 , ... ... Awards were announced today, honoring the businesses, policies, projects, and concepts that are ... a revolutionary bioprinter for living cells, which has taken out the top prize ...
(Date:4/22/2020)... CAMBRIDGE, Mass. (PRWEB) , ... April 20, 2020 ... ... with US offices in Cambridge, MA, announced today that Omixon’s founder and chairman ... early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping into ...
(Date:4/18/2020)... (PRWEB) , ... April 17, 2020 , ... ... Science Foundation (NSF) Small Business Innovation Research (SBIR) program to support the expansion ... This funding from the NSF, which conducts a rigorous merit-based review process, ...
Breaking Biology Technology:
(Date:4/30/2020)... (PRWEB) , ... April 29, 2020 , ... ... well positioned for continued growth – delivering innovative solutions for a wide range ... chemical, aerospace and government agencies. A month into the new decade, it was ...
(Date:4/26/2020)... ... , ... A team of researchers at the Icahn School of Medicine at ... virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus ... , The efforts are being led by Mone Zaidi, MD, PhD, MACP, Director of ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis Biotechnology, Inc. ... firm that provides patent development support for early stage startups. The investment will ... as ovarian cancer and precancerous pancreatic lesions with simple, accurate and practical technology. ...
Breaking Biology News(10 mins):